menu
    • menu

    Company profile for Ernexa Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ernexa Therapeutics is redefining the future of immune modulation through innovative cell therapies that harness the body’s natural healing potential. By addressing immune dysregulation at the root of cancer and autoimmune diseases, Ernexa aims to restore strength, resilience, and hope. Using its proprietary platform, the company engineers induced pluripotent stem cells (iPSCs) into scalable, off-the-shelf induced mesenchyma...
    Ernexa Therapeutics is redefining the future of immune modulation through innovative cell therapies that harness the body’s natural healing potential. By addressing immune dysregulation at the root of cancer and autoimmune diseases, Ernexa aims to restore strength, resilience, and hope. Using its proprietary platform, the company engineers induced pluripotent stem cells (iPSCs) into scalable, off-the-shelf induced mesenchymal stem cells (iMSCs). Its lead candidates, ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, are designed to reactivate and balance immune function for durable, life-changing outcomes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ernexa TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1035 Cambridge St, 18a, Cambridge, Massachusetts 02141
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ernexatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ernexa Therapeutics Prices $10.5M Public Offering
    Ernexa Therapeutics Prices $10.5M Public Offering

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233873/0/en/Ernexa-Therapeutics-Announces-Pricing-of-10-5-Million-Public-Offering.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Ernexa Therapeutics Joins Investor Segment On Pre-Ind Meeting
    Ernexa Therapeutics Joins Investor Segment On Pre-Ind Meeting

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3231107/0/en/Ernexa-Therapeutics-Participates-in-Virtual-Investor-What-This-Means-Segment-Highlighting-Recent-Successful-Pre-IND-Meeting-with-U-S-FDA.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Ernexa Therapeutics Chosen For JETRO Japan Entry Acceleration
    Ernexa Therapeutics Chosen For JETRO Japan Entry Acceleration

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226519/0/en/Ernexa-Therapeutics-Selected-as-One-of-Only-Ten-Global-Companies-for-Prestigious-JETRO-Japan-Entry-Acceleration-Program.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    Ernexa Therapeutics Hits Pre-IND Goal in Ovarian Cancer Trial
    Ernexa Therapeutics Hits Pre-IND Goal in Ovarian Cancer Trial

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213604/0/en/Ernexa-Therapeutics-Announces-Successful-Pre-IND-FDA-Meeting-and-Continues-Progress-Toward-First-in-Human-Trial-in-Ovarian-Cancer.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Ernexa Therapeutics Unveils Preclinical Data On Ovarian Cancer
    Ernexa Therapeutics Unveils Preclinical Data On Ovarian Cancer

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201527/0/en/Ernexa-Therapeutics-Presents-New-Preclinical-Data-at-American-Society-of-Hematology-ASH-Annual-Meeting-on-Lead-Cell-Therapy-Candidate-for-Treatment-of-Ovarian-Cancer.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Ernexa Therapeutics' Oral Presentation at 67th ASH Meeting
    Ernexa Therapeutics' Oral Presentation at 67th ASH Meeting

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198894/0/en/Ernexa-Therapeutics-Announces-Oral-Presentation-at-the-67th-American-Society-of-Hematology-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search